Please check your internet connection and try again.
# Hyaluronic Acid
## Overview
Hyaluronic acid (HA) is a naturally occurring glycosaminoglycan found throughout the body's connective tissues. Exogenous formulations are utilized for intra-articular supplementation, aesthetic dermal fillers, and ophthalmic lubricants. Clinical efficacy varies significantly by molecular weight and route of administration.
## Primary Indications
* **Osteoarthritis (OA):** Symptomatic relief of knee OA in patients failing conservative therapy (NSAIDs/PT).
* **Aesthetics:** Correction of facial wrinkles, folds, and lip augmentation.
* **Ophthalmology:** Dry eye syndrome and ocular surgical aid.
## Adult Dosing
* **Intra-articular (Knee OA):** Dosing is product-specific (e.g., Sodium Hyaluronate or Hylan G-F 20).
* *Standard course:* Usually 20 mg injected into the affected knee once weekly for 3 to 5 weeks.
* *Single-dose formulations:* Some products are administered as a single 6 mL (approx. 48–60 mg) injection.
* **Ophthalmic:** 0.1%–0.3% solution; 1–2 drops instilled into the affected eye(s) as needed.
* **Dermal Fillers:** Variable based on clinical assessment and site; administered by licensed providers.
## Pediatric Dosing
Safety and efficacy have not been established for routine systemic or intra-articular use in pediatrics. Ophthalmic use is generally considered safe but should be directed by pediatric specialist guidelines.
## Dose Adjustments
* **Renal/Hepatic Impairment:** No adjustments required as systemic absorption is negligible for intra-articular and topical preparations.
* **Geriatric:** No specific dose adjustment, but monitor for increased risk of injection site complications if comorbid vascular insufficiency exists.
## Contraindications
* Known hypersensitivity to hyaluronan preparations.
* Known hypersensitivity to avian proteins (for certain avian-derived products).
* Active joint infection (septic arthritis) or skin infection at the intended injection site.
* Severe inflammation of the joint (must be controlled before injection).
## Adverse Effects
* **Intra-articular:** Injection site pain, joint swelling, effusion, transient arthralgia, and rarely, pseudoseptic arthritis (local inflammatory reaction).
* **Ophthalmic:** Blurred vision, transient stinging, or ocular irritation.
* **Dermal:** Erythema, bruising, edema, or rare vascular occlusion (if injected intravascularly).
## Key Drug Interactions
* **Disinfectants:** Do not concurrently use skin disinfectants containing quaternary ammonium salts (e.g., benzalkonium chloride) for injection site preparation, as HA can precipitate in their presence.
* **Other injectables:** Avoid concurrent intra-articular administration with other medications/anesthetics unless directed by protocol.
## Monitoring
* Monitor for signs of acute inflammatory reaction (increased heat/swelling) within 24–48 hours post-injection.
* Assess range of motion and pain reduction scores at follow-up visits.
## Clinical Pearls
* **Efficacy:** Intra-articular HA is generally reserved for patients who have inadequate response to non-pharmacologic measures and simple analgesics.
* **Administration:** Strict aseptic technique is mandatory to avoid iatrogenic septic arthritis.
* **Duration:** Benefits of intra-articular injections typically manifest 4–8 weeks post-injection and may last up to 6 months.
* **Note:** Dosing schedules are highly dependent on the specific brand-name formulation used (e.g., Synvisc, Euflexxa, Hyalgan); always verify the product monograph for specific site/volume instructions.
***
**Educational Disclaimer:** This information is for educational purposes only and does not constitute medical advice. Dosing, indications, and clinical guidelines vary by region and manufacturer. Always consult the current product insert, institutional protocols, and official prescribing information before administering any medication.
